AU9742698A - Amino acid sequences for therapeutical and prophylactic applications to diseasesdue to (clostridium difficile) toxins - Google Patents

Amino acid sequences for therapeutical and prophylactic applications to diseasesdue to (clostridium difficile) toxins

Info

Publication number
AU9742698A
AU9742698A AU97426/98A AU9742698A AU9742698A AU 9742698 A AU9742698 A AU 9742698A AU 97426/98 A AU97426/98 A AU 97426/98A AU 9742698 A AU9742698 A AU 9742698A AU 9742698 A AU9742698 A AU 9742698A
Authority
AU
Australia
Prior art keywords
toxins
clostridium difficile
diseasesdue
therapeutical
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU97426/98A
Other languages
English (en)
Inventor
Michael Moos
Christoph Von Eichel-Streiber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VON EICHEL STREIBER CHRISTOPH
Original Assignee
VON EICHEL STREIBER CHRISTOPH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VON EICHEL STREIBER CHRISTOPH filed Critical VON EICHEL STREIBER CHRISTOPH
Publication of AU9742698A publication Critical patent/AU9742698A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU97426/98A 1997-09-10 1998-09-10 Amino acid sequences for therapeutical and prophylactic applications to diseasesdue to (clostridium difficile) toxins Abandoned AU9742698A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19739685 1997-09-10
DE19739685A DE19739685A1 (de) 1997-09-10 1997-09-10 Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
PCT/EP1998/005759 WO1999012971A2 (de) 1997-09-10 1998-09-10 Aminosäuresequenzen zur therapie und prophylaxe von erkrankungen durch clostridium difficile toxine

Publications (1)

Publication Number Publication Date
AU9742698A true AU9742698A (en) 1999-03-29

Family

ID=7841840

Family Applications (1)

Application Number Title Priority Date Filing Date
AU97426/98A Abandoned AU9742698A (en) 1997-09-10 1998-09-10 Amino acid sequences for therapeutical and prophylactic applications to diseasesdue to (clostridium difficile) toxins

Country Status (11)

Country Link
US (2) US6667035B1 (https=)
EP (1) EP0994904B1 (https=)
JP (1) JP4318398B2 (https=)
CN (1) CN1273588A (https=)
AT (1) ATE254139T1 (https=)
AU (1) AU9742698A (https=)
BR (1) BR9815367A (https=)
CA (1) CA2303202C (https=)
DE (2) DE19739685A1 (https=)
ES (1) ES2210832T3 (https=)
WO (1) WO1999012971A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
WO2002062379A2 (en) * 2001-02-09 2002-08-15 The Provost, Fellows And Scholars Of The College Of The Holy And Unidivided Trinity Of Queen Elizabeth Clostridium difficile vaccine
GB0130267D0 (en) * 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
GB0205206D0 (en) * 2002-03-06 2002-04-17 Oxoid Ltd Synthetic peptides
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
LT2857418T (lt) 2004-02-06 2017-09-25 University Of Massachusetts Antikūnai prieš clostridium difficile toksinus ir jų panaudojimas
ATE385423T1 (de) * 2004-06-16 2008-02-15 Straumann Holding Ag Abdeckmembran
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
US20090087478A1 (en) * 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
CA2618796C (en) 2005-08-11 2018-01-02 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmune disease
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
CA2680741A1 (en) 2007-03-22 2009-01-15 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20090280134A1 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting toxin a from clostridium difficile
DE102008029688B4 (de) * 2008-06-24 2016-06-23 Biodics Gmbh Verfahren zum Nachweis und zur Identifikation eines varianten C. difficile Stammes in einer Probe
WO2010014854A2 (en) 2008-07-31 2010-02-04 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
US8889363B2 (en) 2009-07-27 2014-11-18 Biodics Method for the detection and identification of a variant C. difficile strain in a sample
CA2768528C (en) * 2009-07-27 2017-05-23 Christoph Von Eichel-Streiber Method for detecting and identifying a variant c. difficile strain in a sample
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
WO2012118693A1 (en) * 2011-02-28 2012-09-07 Northshore University Healthsystem Methods of diagnosing clostridium difficile infection
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
US9505847B2 (en) * 2011-08-22 2016-11-29 Cnj Holdings Inc Clostridium difficile antibodies
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
HK1200463A1 (en) * 2012-03-02 2015-08-07 瑞泽恩制药公司 Human antibodies to clostridium difficile toxins
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN109776676A (zh) * 2012-11-28 2019-05-21 Cnj控股公司 针对艰难梭菌的抗体
EP4079760A3 (en) 2013-03-15 2023-01-25 Sanofi Pasteur Inc. Antibodies against clostridium difficile toxins and methods of using the same
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
DE3471661D1 (en) 1984-03-02 1988-07-07 Tracy Dale Wilkins Toxins and antibodies of c. difficile
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4863852A (en) 1985-07-03 1989-09-05 Virginia Tech Intellectual Properties, Inc. Method of detecting, isolating and purifying clostridium difficile toxin A and its receptors
US5071759A (en) * 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US5580774A (en) * 1989-07-31 1996-12-03 Eli Lilly And Company Chimeric antibodies directed against a human glycoprotein antigen
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5098826A (en) 1990-03-09 1992-03-24 Virginia Tech Intellectual Properties, Inc. Detection, isolation and purification of Clostridium difficile toxin A with toxin receptors
US5231003A (en) * 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5858725A (en) 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9317423D0 (en) * 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
CA2203504A1 (en) * 1994-10-24 1996-05-02 James A. Williams Vaccine and antitoxin for treatment and prevention of c. difficile disease
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile

Also Published As

Publication number Publication date
DE19739685A1 (de) 1999-03-11
ES2210832T3 (es) 2004-07-01
JP2001515920A (ja) 2001-09-25
BR9815367A (pt) 2001-11-06
EP0994904B1 (de) 2003-11-12
CA2303202A1 (en) 1999-03-18
EP0994904A2 (de) 2000-04-26
ATE254139T1 (de) 2003-11-15
JP4318398B2 (ja) 2009-08-19
WO1999012971A3 (de) 1999-07-22
US7151159B2 (en) 2006-12-19
CA2303202C (en) 2010-04-27
US6667035B1 (en) 2003-12-23
DE59810172D1 (de) 2003-12-18
CN1273588A (zh) 2000-11-15
WO1999012971A2 (de) 1999-03-18
US20040137601A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
AU9742698A (en) Amino acid sequences for therapeutical and prophylactic applications to diseasesdue to (clostridium difficile) toxins
AU7240096A (en) Neutralizing monoclonal antibodies to respiratory syncytial virus
LUC00074I2 (en) Method for controlling the activity of immunologically functional molecule
WO2003016467A3 (en) Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
FI942237A0 (fi) Lysosomaalientsyymin pilkkoamia kasvaintenvastaisia lääkeainekonjugaatteja
AU3539997A (en) Recognition molecules interacting specifically with the active site or cleft of a target molecule
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
WO2002082041A3 (en) Production and use of novel peptide-based agents for use with bi-specific antibodies
AU2002355677A1 (en) Antigenic polypeptides
ATE267254T1 (de) Isolierte peptide, die mit mhc mulekül hla-c-klon 10 komplexe bilden und ihre verwendungen
BRPI0013885B8 (pt) comprimidos aperfeiçoados
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
WO2003030835A3 (en) Use of bispecific antibodies to regulate immune responses
WO2004020579A3 (en) Method of humanizing immune system molecules
WO2002075274A3 (fr) Methode et trousse pour le suivi des maladies neurodegeneratives
HUP0103573A2 (hu) Trombózis elleni hatóanyag és von Willebrand faktor elleni monoklonális antitest
EP2261253A3 (en) Antibodies directed to Clostridium difficile
AU4897096A (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen
IL187595A0 (en) Antitumor antibodies, proteins, and uses thereof
DK0635025T3 (da) Fremgangsmåde til fremstilling af modificerede proteiner
WO2002094881A3 (en) Monoclonal antibody neutralising cathepsin b activity and uses thereof
AU4114800A (en) Monoclonal antibodies against human protein mcm3, process for their production, and their use
SI1267937T1 (sl) Polisaharid-polipeptidni konjugat
AU2003218743A1 (en) Detection of specific nitrated protein markers
WO2002007740A3 (de) Schlangentoxin und dessen verwendung als arzneimittel

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase